http://www.jcog.jp/en/trials/index.html WebTadahiko Shien, Tomonori Mizutani, Kiyo Tanaka, Takayuki Kinoshita, Fumikata Hara, et al. (2024) A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (JCOG 1017 PRIM-BC). Journal of Clinical Oncology 35.

Resection of the primary tumor in stage IV breast cancer

Web24 lug 2012 · A Randomized Controlled Trial Comparing Primary Tumour Resection Plus Systemic Therapy With Systemic Therapy Alone in Metastatic Breast Cancer (PRIM-BC): … Web臨床研究等提出・公開システム. 臨床研究・治験計画情報の詳細情報です。. JCOG1017: 薬物療法非抵抗性Stage IV 乳癌に対する原発巣切除の意義（原発巣切除なしversus あり）に関するランダム化比較試験. JCOG1017: 薬物療法非抵抗性Stage IV 乳癌に対する原発巣切 … tag agency clermont fl

Does aggressive local therapy improve survival in metastatic breast ...

WebJCOG9803. Feasibility. A feasibility study of Quality-of-life (QOL) evaluation in a randomized phase III trial of doxorubicin (A)/cyclophosphamide (C) (AC), docetaxel (D), and … WebCore tip: Resection of a primary tumor of stage IV breast cancer was considered to be “effective only at alleviating chest symptoms and providing local control” in spite of the advances of imaging examination and medication for breast cancer. Recently, many retrospective studies have reported the survival benefit of surgery for breast cancer … WebThe Japan Clinical Oncology Group (JCOG 1017) and Eastern Clinical Oncology Group (ECOG 2108) are enrolling and following patients for a phase 3 trial . In these trials, patients received the most up-to-date standard systemic therapy available before and after randomization, and also the most advanced form of imaging examination available … tag agency enid hours